IMPORTANT CO-PAY INFORMATION

Ryplazim®
plasminogen, human-tvmh

Eligibility Guidelines

To be eligible for co-pay assistance up to $20,000 annually, patients must:

- Be prescribed RYPLAZIM for the treatment of plasminogen deficiency type I
- Be commercially insured
- Express financial need

Restrictions

- Not valid for prescriptions eligible for reimbursement by any federal or state healthcare programs, such as Medicare, Medicaid, Medigap, Veterans Affairs, Department of Defense, Tricare, or any other federal or state-funded programs.
- Claims must be received within 30 days of dispense date.
- **EOBs must also be submitted within 120 days of the claim submission date.**

Enrollment Registration

The enrollment process is as easy as 1-2-3:

1. **Scan the QR code** to open the Medmonk RYPLAZIM Co-pay Assistance Program portal at https://ryplazim.medmonk.com.
2. If you are new to Medmonk, use the **Provider Registration** link to register your pharmacy for instant adjudication.
3. Use the **Provider Login** to begin the patient enrollment and eligibility check.

INDICATIONS AND USAGE

RYPLAZIM® (plasminogen, human-tvmh) is a plasma-derived human plasminogen indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

RYPLAZIM is contraindicated in patients with known hypersensitivity to plasminogen or other components of RYPLAZIM.

WARNINGS AND PRECAUTIONS:

- Bleeding: RYPLAZIM administration may lead to bleeding at active mucosal disease-related lesion sites or worsen active bleeding not related to disease lesions. Discontinue RYPLAZIM if serious bleeding occurs. Monitor patients during and for 4 hours after infusion when administering RYPLAZIM to patients with bleeding diatheses and patients taking anticoagulants, antiplatelet drugs, or other agents which may interfere with normal coagulation.

Please see additional important safety information on back and accompanying Full Prescribing Information.

GET IN TOUCH

Ryplazim®
plasminogen, human-tvmh

Please contact Kedrion Connects™ with additional questions.

Kedrion Connects™ Support Services
Phone: 888-262-8040
Fax: 408-419-1768

Contact Kedrion Biopharma

Kedrion Biopharma Commercial Rare Disease Team	Kedrion Biopharma Customer Service
Jamie Mattern, **National Rare Disease Sales Director** **Email:** j.mattern@kedrion.com **Cell:** 609-464-1295 **Patricia Underland,** **Clinical Nurse Educator** **Email:** p.underland@kedrion.com **Cell:** 201-401-0918 **Mindy Eldridge,** **Clinical Nurse Educator** **Email:** m.eldridge@kedrion.com **Cell:** 913-608-6504	**Website:** **Phone:** 855-353-7466 **Fax:** 855-751-7951 **Email:** kedrioncs@icsconnect.com **Hours:** Monday–Friday 7:00 a.m.–7:00 p.m. CT

IMPORTANT SAFETY INFORMATION, cont.

WARNINGS AND PRECAUTIONS, cont.

- Tissue Sloughing: Respiratory distress due to tissue sloughing may occur in patients with mucosal lesions in the tracheobronchial tree following RYPLAZIM administration. Please monitor appropriately.
- Transmission of Infectious Agents: RYPLAZIM is made from human plasma and therefore carries a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob Disease (CJD) agent.
- Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis, may occur with RYPLAZIM. If symptoms occur, discontinue RYPLAZIM and administer appropriate treatment.
- Neutralizing Antibodies: Neutralizing antibodies (inhibitors) may develop, although they were not observed in clinical trials. If clinical efficacy is not maintained (e.g., development of new or recurrent lesions), determine plasminogen activity trough levels in plasma.
- Laboratory Abnormalities: Patients receiving RYPLAZIM may have elevated blood levels of D-dimer. D-dimer levels will lack interpretability in patients being screened for venous thromboembolism (VTE).

ADVERSE REACTIONS:

The most frequent (incidence ≥ 10%) adverse reactions in clinical trials were abdominal pain, bloating, nausea, fatigue, extremity pain, hemorrhage, constipation, dry mouth, headache, dizziness, arthralgia, and back pain.

To report SUSPECTED ADVERSE REACTIONS, contact KEDRION at 1-855-427-6378 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information on front and accompanying Full Prescribing Information.

Kedrion Biopharma